Novartis India Limited
Novartis India Limited (NOVARTIND) financial statements and selected valuation metrics from NSE/BSE exchange filings through 31 December 2025.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
novartis.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-03
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Standalone
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Only standalone filings are available for this company.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 76 Cr | 91 Cr | 79 Cr | 85 Cr | 81 Cr | 92 Cr | 87 Cr | 93 Cr | 84 Cr | 88 Cr | 90 Cr | 86 Cr |
| Operating expenses (approx.) | 67 Cr | 73 Cr | 62 Cr | 65 Cr | 70 Cr | 68 Cr | 69 Cr | 67 Cr | 60 Cr | 60 Cr | 66 Cr | 64 Cr |
| EBITDA | 9 Cr | 17 Cr | 17 Cr | 20 Cr | 11 Cr | 24 Cr | 18 Cr | 26 Cr | 24 Cr | 27 Cr | 24 Cr | 22 Cr |
| OPM % | 12.2% | 19.1% | 21.5% | 23.4% | 13.8% | 26.0% | 20.6% | 27.5% | 28.5% | 31.1% | 26.4% | 26.0% |
| Other income | 16 Cr | 12 Cr | 17 Cr | 22 Cr | 10 Cr | 10 Cr | 10 Cr | 11 Cr | 11 Cr | 11 Cr | 9 Cr | 9 Cr |
| Interest | 0.30 Cr | 0.46 Cr | 0.71 Cr | 0.16 Cr | 0.16 Cr | 0.15 Cr | 0.14 Cr | 0.36 Cr | 0.12 Cr | 0.10 Cr | 0.11 Cr | 0.98 Cr |
| Depreciation | 2 Cr | 2 Cr | 0.65 Cr | 0.26 Cr | 0.14 Cr | 0.55 Cr | 0.58 Cr | 0.53 Cr | 0.53 Cr | 0.53 Cr | 0.52 Cr | 0.48 Cr |
| Profit before tax | 23 Cr | 28 Cr | 32 Cr | 41 Cr | 21 Cr | 34 Cr | 28 Cr | 35 Cr | 34 Cr | 37 Cr | 33 Cr | 30 Cr |
| Tax % | -7.3% | 27.0% | 27.0% | 35.7% | 31.2% | 23.6% | 25.9% | 27.9% | 13.5% | 25.8% | 25.8% | 45.7% |
| Net profit | 25 Cr | 20 Cr | 24 Cr | 27 Cr | 15 Cr | 26 Cr | 20 Cr | 25 Cr | 29 Cr | 28 Cr | 24 Cr | 16 Cr |
| EPS (₹) | ₹10.13 | ₹8.21 | ₹9.59 | ₹10.76 | ₹5.95 | ₹10.42 | ₹8.27 | ₹10.31 | ₹11.87 | ₹11.19 | ₹9.81 | ₹6.52 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 491 Cr | 438 Cr | 381 Cr | 400 Cr | 379 Cr | 335 Cr | 356 Cr | Sign in for TTM |
| Operating expenses (approx.) | 478 Cr | 426 Cr | 355 Cr | 373 Cr | 314 Cr | 270 Cr | 265 Cr | Sign in for TTM |
| EBITDA | 12 Cr | 12 Cr | 27 Cr | 27 Cr | 65 Cr | 65 Cr | 91 Cr | Sign in for TTM |
| OPM % | 2.5% | 2.7% | 7.0% | 6.8% | 17.2% | 19.5% | 25.7% | Sign in for TTM |
| Other income | 78 Cr | 36 Cr | 33 Cr | 33 Cr | 58 Cr | 62 Cr | 42 Cr | Sign in for TTM |
| Interest | 2 Cr | 6 Cr | 8 Cr | 5 Cr | 2 Cr | 1 Cr | 0.77 Cr | Sign in for TTM |
| Depreciation | 3 Cr | 13 Cr | 12 Cr | 10 Cr | 6 Cr | 3 Cr | 2 Cr | Sign in for TTM |
| Profit before tax | 86 Cr | 29 Cr | 40 Cr | -4 Cr | 115 Cr | 123 Cr | 130 Cr | Sign in for TTM |
| Tax % | 39.6% | 64.8% | 47.8% | 2.6% | 10.4% | 30.6% | 22.6% | Sign in for TTM |
| Net profit | 52 Cr | 10 Cr | 21 Cr | -4 Cr | 103 Cr | 85 Cr | 101 Cr | Sign in for TTM |
| EPS (₹) | ₹20.97 | ₹4.08 | ₹8.46 | ₹-1.51 | ₹41.86 | ₹34.50 | ₹40.87 | Sign in for TTM |
| Dividend payout % | — | — | — | — | 23.9% | 137.7% | 61.2% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Equity capital | 12 Cr | 12 Cr | 12 Cr | 12 Cr | 12 Cr | 12 Cr | 12 Cr |
| Reserves | 747 Cr | 708 Cr | 699 Cr | 679 Cr | 763 Cr | 732 Cr | 773 Cr |
| Borrowings | — | — | — | — | — | 0.02 Cr | — |
| Other liabilities | 223 Cr | 357 Cr | 291 Cr | 266 Cr | 207 Cr | 180 Cr | 163 Cr |
| Total liabilities | 982 Cr | 1,078 Cr | 1,002 Cr | 958 Cr | 983 Cr | 925 Cr | 948 Cr |
| Fixed assets (net) | 15 Cr | 76 Cr | 64 Cr | 24 Cr | 19 Cr | 7 Cr | 5 Cr |
| CWIP | — | — | 0 Cr | 0 Cr | 0 Cr | 0 Cr | 0 Cr |
| Investments | 0 Cr | 0 Cr | 0 Cr | 0 Cr | 0 Cr | 0 Cr | 0 Cr |
| Loans & advances | 0.06 Cr | 0.06 Cr | 0.06 Cr | 0.46 Cr | 0 Cr | 0 Cr | 0 Cr |
| Inventories | 61 Cr | 59 Cr | 48 Cr | 57 Cr | 55 Cr | 45 Cr | 41 Cr |
| Trade receivables | 46 Cr | 38 Cr | 39 Cr | 45 Cr | 36 Cr | 41 Cr | 40 Cr |
| Cash & bank | 88 Cr | 79 Cr | 68 Cr | 158 Cr | 19 Cr | 45 Cr | 52 Cr |
| Other assets | 774 Cr | 826 Cr | 783 Cr | 673 Cr | 853 Cr | 787 Cr | 810 Cr |
| Total assets | 982 Cr | 1,078 Cr | 1,002 Cr | 958 Cr | 983 Cr | 925 Cr | 948 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 39 Cr | 45 Cr | 113 Cr | 75 Cr |
| Cash from investing | — | — | — | 87 Cr | -153 Cr | 33 Cr | -3 Cr |
| Cash from financing | — | — | — | -36 Cr | -30 Cr | -121 Cr | -64 Cr |
| Net cash flow | — | — | — | 90 Cr | -139 Cr | 26 Cr | 7 Cr |
| Free cash flow (OCF − Capex) | — | — | — | 38 Cr | 44 Cr | 113 Cr | 75 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| ROCE % | 11.5% | 4.9% | 6.7% | 0.1% | 15.1% | 16.7% | 16.7% |
| ROE % | 6.8% | 1.4% | 2.9% | -0.5% | 13.3% | 11.4% | 12.9% |
| Debtor days | 34 | 31 | 37 | 41 | 35 | 45 | 41 |
| Inventory days | 45 | 49 | 46 | 52 | 53 | 49 | 42 |
| Days payable | 68 | 60 | 53 | 66 | 57 | 67 | 53 |
| Cash conversion cycle | 11 | 20 | 30 | 27 | 30 | 27 | 30 |
| Debt / equity | — | — | — | — | 0.00 | 0.0000 | — |
| Current ratio | 4.35 | 3.49 | 4.55 | 3.27 | 4.25 | 4.45 | 5.25 |
| Net debt / EBITDA | -7.15 | -6.58 | -2.55 | -5.84 | -0.30 | -0.69 | -0.57 |
Compare with peers
Loading peers…